Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin

Halkes, P. H. A.; van Gijn, J.; Kappelle, L. J.; Koudstaal, P. J.; Algra, A.
April 2009
Journal of Neurology, Neurosurgery & Psychiatry;Apr2009, Vol. 80 Issue 4, p437
Academic Journal
A considerable proportion of patients discontinue dipyridamole therapy because of headache. Risk indicators for the development of dipyridamole induced headache were identified by means of an exploratory analysis of data from the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) and the Second European Stroke Prevention Study (ESPS 2). In ESPRIT, dipyridamole induced headache was significantly associated with female sex, absence of hypertension and non-smoking (area under the receiver operator characteristic (ROC) curve 0.63 (95% CI 0.58 to 0.68)) and in ESPS 2 with female sex and absence of ischaemic lesions on imaging (area under the ROC curve 0.64 (95% CI 0.59 to 0.69)).


Related Articles

  • Dual therapy after stroke to prevent recurrence. Kirchner, Jeff; Russell, John J. // Patient Care;Aug2006, Vol. 40 Issue 8, p59 

    The article discusses a study by P. H. Halkes and colleagues on dual therapy for secondary stroke prevention, published in the 2006 issue of "Lancet." The study randomized 2700 patients to aspirin with or without dipyridamole following a minor stroke or transient ischemic attack. The primary...

  • The PROGRESS trial three years later: time for a balanced report of effectiveness. Wennberg, Richard; Zimmermann, Camilla // BMJ: British Medical Journal (International Edition);10/23/2004, Vol. 329 Issue 7472, p968 

    Reports on the results of the three-year PROGRESS trial, which studied perindopril protection against stroke. Findings that blood pressure lowering was safe and effective; Details of the trial; Requirements of the patients who had had a stroke or transient ischaemic attack in the previous five...

  • Recombinant Activated Factor VIIa: Phase III Trial Fails to Show Clinical Benefit. Segal, Alan Z. // Neurology Alert;Jul2008, Vol. 26 Issue 11, p86 

    RANDOMIZED STUDIES OF NEUROPROTECTIVE AGENTS for ischemic stroke have resulted in a series of failures, as multiple agents, promising in animal models, have failed when applied to human subjects. By contrast, intracerebral hemorrhage (ICH), has been somewhat a "neglected stepsister" when...

  • Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke. McCabe, D. J. H.; Rakhit, R. D. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2007, Vol. 78 Issue 1, p14 

    Peer-reviewed data pertaining to anti-thrombotic and interventional therapy for transient ischaemic attack (TIA) or ischaemic stroke patients with non-valvular atrial fibrillation, atrial flutter, interatrial septal abnormalities, or left ventricular thrombus were reviewed. Long-term oral...

  • Primary central nervous system vasculitis and moyamoya disease: similarities and differences. Kraemer, Markus; Berlit, Peter // Journal of Neurology;May2010, Vol. 257 Issue 5, p816 

    Primary central nervous system vasculitis (PCNSV) and moyamoya disease (MMD) represent rare and poorly-understood causes of stroke. Both may present with similar clinical and auxiliary findings, but differentiation is extremely important because they require different treatment regimens. Our...

  • CITATIONS AND CLINICIANS' NOTES: Acute Stroke Treatment.  // Current Medical Literature: Stroke Review;2005, Vol. 9 Issue 1, p136 

    Presents articles about acute stroke treatment which can be useful to clinicians. "The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase," by W. Hacke, G. Albers, Y. Al-Rawi et al.;...

  • REGISTRO RETROSPECTIVO DE FACTORES ASOCIADOS AL DESARROLLO DE EVENTOS CEREBROVASCULARES EN GUAYAQUIL. Guzmán Adum, Ivette; Alarcón, Carolina Mora; Tettamanti Miranda, Daniel // Revista Medicina;2015, Vol. 19 Issue 1, p25 

    Background: in 2010 the INEC reported that in Ecuador cerebrovascular accidents (CVA) are the fifth leading cause of death (5.3%). The most common clinical presentation, evolution, and degree of residual disability are unknown. Therefore, medical practice is largely based on international...

  • Stroke Recurrence and its Prevention in Patients with Patent Foramen Ovale. Harrer, J. U.; Wessels, T.; Franke, A.; Lucas, S.; Berlit, P.; Klötzsch, C. // Canadian Journal of Neurological Sciences;Feb2006, Vol. 33 Issue 1, p39 

    The article presents a study on the cause of stroke recurrence and preventive measures in patients with patent foramen ovale (PFO). Respondents of the study were patients with cryptogenic cerebral ischemia and PFO. Results showed that annual stroke recurrence rates were generally low and...

  • PROGRESS IN CLINICAL NEUROSCIENCES: Migraine-Stroke: A Causal Relationship, but Which Direction? Kern, Ralph Z. // Canadian Journal of Neurological Sciences;Nov2004, Vol. 31 Issue 4, p451 

    Focuses on the association between migraine and ischemic stroke in population and case-control studies. Degree of risk of ischemic stroke in migraine with aura compared with migraine without aura; Distinct entities of migraine-stroke; Evaluation of clinical studies on the bidirectional...


Read the Article


Sign out of this library

Other Topics